Novartis Ag

Novartis Pharma Gmbh

David Raymond Stover

Guido Bold

Peter Traxler

Karl-Heinz Altmann

Jeanette Marjorie Wood

J&ouml;rg Frei

Helmut Mett

Bruno Dombrecht

Joost Alexander Kolkman

Josef Prassler

Jing Li

Karen Cromie

Seth Alexander Ettenberg

Catrin Berger

Bodo Brocks

Kris Meerschaert

Jingxin Zhang

The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also 'DR5'), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as 'NB agents') and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.

Biologic compounds directed against death receptor 5

Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a c-Met-related condition such as a cancer, a metastasis, or an inflammatory condition.

Compositions and methods of use for antibodies of c-Met

Phthalazines with angiogenesis inhibiting activity

Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity

The invention relates to compounds of formula I,

Growing community of inventors

Wilmington, MA, United States of America

David Raymond Stover